Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

Inclusion Criteria: * HIV-1 infection, documented by any licensed HIV test * Male subjects ≥ 18 years of age * Identify as MSM (men who have sex with men) * Currently on continuous ART for ≥24 weeks prior to study entry with no change in the ART regimen within the 12 weeks prior to study * Ability and willingness of the participating subject to sign the informed consent form * No plan to change ART regimen for the study duration * Screening CD4+ cell count \>350 cells/mm3 obtained within 45 days prior to study entry * HIV RNA \< 20 copies/ml for ≥12 weeks (1 blip of \< 500 copies/ml will be permitted) * Absolute neutrophil count ≥ 1000 cells/mm3 Exclusion Criteria: * Initiation of ART during acute/early HIV infection (within 6 months of HIV seroconversion) * Co-infection with Hepatitis B (positive HBsAg or positive HBcAb total with detectable HBV DNA levels) or Hepatitis C (positive HCV IgG with detectable HCV RNA levels) * Use of antibiotics 60 days prior to the study entry * Use of investigational therapies or vaccines 60 days prior to the study entry * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry * Cirrhosis, inflammatory bowel disease, total colectomy, colon or rectal anastomosis, bowel resection, or current colostomy * Diabetes mellitus * Any episode of acute or persistent diarrhea within 60 days prior to study entry * Use of any of the following medications/products for more than 3 consecutive days within the 60 days prior to study entry: Immunosuppressives, Immune modulators, Antineoplastic agents (except for topical agents for skin cancer), Probiotics and prebiotics (supplements and products).